calculating ABW are available, the most commonly used formula is: ABW = [(Actual Body Weight -Ideal Body Weight)(0.4)] + Ideal Body Weight. Ideal Body Weight (IBW) is most commonly calculated as 25 : IBW = 50 kg + 2.3 kg/inch >60 inch (Men) IBW = 45.5 kg + 2.3 kg/inch >60 inch (Women) 3. If the patient has a serum creatinine less than 0.8 mg/dL, round the serum creatinine up to 0.8 mg/dL. 24, 26 The Gynecologic Oncology Group has suggested rounding values less than 0.7 mg/ dL up to 0.7 mg/dL. 27 4. Use of GFR values higher than 125 mL/min to calculate carboplatin doses by Calvert's method may be appropriate in selected patients. Calvert reported measured GFRs as high as 180 mL/min and used measured GFRs up to 136 mL/min to calculate carboplatin doses. 19 The US Food and Drug Administration (FDA) recommends that CrCl greater than 125 mL/min, as estimated by the Cockcroft 6 3. Liposomal doxorubicin 40 mg/m 2 and carboplatin AUC = 5 or 6 every 4 weeks. 8 4. Liposomal doxorubicin 50 mg/m 2 and carboplatin AUC = 5 every 4 weeks. 10 5. Liposomal doxorubicin 45 mg/m 2 and carboplatin AUC = 5 every 4 weeks. 12
Note: AUC = area under the time vs concentration curve; IV = intravenous. Volume 51, June 2016 4. The liposomal doxorubicin was administered after the carboplatin in 2 of the trials reviewed. 2, 17 
SUPPORTIVE CARE
A. Acute and Delayed Emesis Prophylaxis The carboplatin plus PLD regimen is predicted to cause acute emesis in 30% to 90% of patients. [31] [32] [33] [34] The studies reviewed reported nausea in 28% to 86% and vomiting in 43% to 49% of patients. 1, [3] [4] [5] 8, 10, 14, 16 Severe (grade 3 or 4) nausea or vomiting was reported in 3% to 10% of patients. [3] [4] [5] 8, 10, 14, 16 Prophylactic antiemetic therapy with a serotonin antagonist and a corticosteroid is recommended. One of the following regimens given 30 minutes prior to PLD is recommended for acute emesis prophylaxis. Antiemetic therapy should continue for at least 2 additional days. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (>24 hours) use of these agents; making a steroid, or steroid and dopamine antagonist combination, most appropriate for follow-up therapy. 35 If a neurokinin antagonist is used on day 1, then aprepitant 80 mg PO once daily for 2 days should be added to one of the regimens above, starting on day 2. One of the following regimens is recommended: [31] [32] [33] [34] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles or increasing the dose, even to very high doses, is effective. This approach is not recommended. [36] [37] [38] [39] [40] Although carboplatin is reported to cause delayed nausea or emesis similar to cisplatin, the mechanism of action and clinical course of carboplatin-induced nausea and vomiting differ from cisplatin. 41, 42 Analysis of urinary 5-hydroxyindole acetic acid (5-HIAA) excretion indicates carboplatin causes a lower peak level but more prolonged release of serotonin than cisplatin. The clinical course of carboplatin-induced emesis reflects this pattern of serotonin release. Carboplatin-induced emesis usually begins 6 to 7 hours after drug administration and may persist for up to 120 hours. Although not well documented in the literature, some clinicians divide the daily antiemetic dose into 2 doses on days when carboplatin is administered.
B. Breakthrough Nausea and Vomiting 31-34 : Patients
should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is recommended: 46 For severe or repeated reactions, desensitization to carboplatin may be done. 47 ,48 E. Hematopoietic Growth Factors: Accepted practice guidelines and pharmacoeconomic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. 49 For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 49, 50 Since febrile neutropenia was reported in 2% to 10% of patients in the trials reviewed, 1, 3, 4, 10, 14, 16 prophylactic use of CSFs is not recommended. CSFs should be considered if a patient develops febrile neutropenia grade 4 in a prior cycle of CD. 49, 50 MAJOR TOXICITIES Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).
Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities; but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Arrythmia (grade 2) 2%, 10 (grade 3 or 4) 1% 10 ; unspecified cardiac reactions 11%, 1 (grade 2) 2%, 14 a. Greater than equal to 100,000 cells/mcL. 2, 4 b. Greater than equal to 75,000 cells/mcL. 5 5. Hemoglobin: Greater than or equal to 10 g/dL. 4,5 6. Serum creatinine: a. Less than or equal to 1.9 mg/dL. 4 b. Less than or equal to 1.5 times the upper limit of normal (ULN). 5 c. Less than or equal to 1.25 times the ULN. 3 7. Serum bilirubin: a. Less than or equal to the ULN. 4 b. Less than or equal to 1.25 times the ULN. 3 
AST/ALT:
a. Less than equal to 2 times the ULN. 4, 5 b. Less than equal to 5 times the ULN with liver metastases. 3 9. Alkaline phosphatase: Less than equal to 2 times the ULN. 4,5 10. Left ventricular ejection fraction (LVEF):
Greater than or equal to 50% measurement by echocardiogram if cumulative anthracycline dose exceeded 450 mg/m 2 . 1, 5 In clinical practice, a pretreatment absolute neutrophil count (ANC) of 1,000 cells/mcL and platelets of 75,000 cells/mcL are usually considered acceptable. (1) grade 4 neutropenia (2) febrile neutropenia (3) granulocyte count less than 500/mcL for greater than or equal to 7 days (4) granulocyte count less than 1,000/mcL for greater than or equal to 3 days (5) thrombocytopenia (6) severe bleeding. b. Hold dose until full recovery for 1 :
DOSAGE MODIFICATIONS
(1) prolonged neutropenia (2) thrombocytopenia up to 14 days. c. Neutrophils less than 1,500 cells/mcL or platelets less than 50,000 cells/mcL for more than 7 days, reduce the dose of both drugs 20%. 17 17 : a. Palmar-plantar erythrodysesthesia (1) greater than or equal to grade 2, delay therapy for up to 2 weeks. (2) grade 3 or 4 that does not resolve in 2 weeks, reduce the dose 25%.
